文献速递冠心病

静脉尼可地尔在接受直接PCI的STEMI患者中的疗效:CLEAN随机临床试验

Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI: The CLEAN Randomized Clinical Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-08-12

CLEAN试验为多中心、随机、双盲、安慰剂对照研究,纳入中国49家医院的1503例STEMI患者,比较直接PCI前静脉注射尼可地尔(再灌注前6mg推注,继以6mg/h持续48小时)与安慰剂对12个月临床结局的影响。主要复合终点(心血管死亡、非致死性心肌梗死、靶血管血运重建或心力衰竭非计划住院)在两组均为13.1%,无显著差异,提示不推荐常规使用静脉尼可地尔。

要点

  • 静脉尼可地尔未显著降低STEMI患者12个月主要复合终点(13.1% vs 13.1%,P=0.3429)。
  • 次要终点中,心血管死亡(1.9% vs 3.6%)和靶血管血运重建(1.1% vs 3.0%)名义上有减少。
  • 研究不支持对未经选择的STEMI患者常规使用静脉尼可地尔。

核心结论

  • 在接受直接PCI的STEMI患者中,辅助静脉尼可地尔未显著降低12个月主要复合终点,不支持常规使用。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,在中国49家医院进行,纳入年龄18-80岁、症状发作12小时内STEMI患者,按1:1随机分配至静脉尼可地尔(再灌注前6mg推注,继以6mg/h输注48小时)或安慰剂,随访12个月,主要终点为心血管死亡、非致死性心肌梗死、靶血管血运重建或心力衰竭非计划住院的复合终点。

主要发现

  • 共纳入1503例患者(尼可地尔748例,安慰剂755例);主要复合终点发生率分别为13.1%和13.1%,无显著差异(率比0.869,95%CI 0.650-1.162,P=0.3429);次要终点中,心血管死亡(1.9% vs 3.6%,HR 0.515,95%CI 0.269-0.983)和靶血管血运重建(1.1% vs 3.0%,HR 0.322,95%CI 0.143-0.727)名义上降低,但非致死性心肌梗死和心力衰竭住院相似;不良事件两组无差异。

关键数值与推荐

  • 主要终点复合结局发生率:尼可地尔组13.1%(113事件/717.2人年),安慰剂组13.1%(136事件/710.3人年),率比0.869,95%CI 0.650-1.162,P=0.3429;心血管死亡HR 0.515(95%CI 0.269-0.983),靶血管血运重建HR 0.322(95%CI 0.143-0.727)。

临床怎么用

  • 临床不推荐对全部STEMI患者常规使用静脉尼可地尔,但次要终点中死亡和血运重建的潜在获益提示特定亚组或需进一步研究。

局限性

  • 次要终点的名义性降低未校正多重比较,结果需谨慎解读;研究在中国进行,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nicorandil, an adenosine triphosphate-sensitive potassium-channel opener with nitrate-like properties, may reduce reperfusion injury and microvascular obstruction in ST-segment elevation myocardial infarction (STEMI), but large-scale randomized evidence on long-term clinical outcomes is inconclusive. OBJECTIVES: The CLEAN trial aimed to assess whether adjunctive intravenous nicorandil improves 12-month clinical outcomes in patients with STEMI undergoing primary percutaneous coronary intervention. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial conducted at 49 hospitals in China, patients aged 18 to 80 years with STEMI within 12 hours of symptom onset were randomly assigned (1:1) to receive intravenous nicorandil (6 mg bolus before reperfusion followed by 6 mg/h infusion for 48 h) or matching placebo. Oral nicorandil was prohibited during follow-up. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, target vessel revascularization, or unplanned hospitalization for heart failure within 12 months. RESULTS: Between January 2021 and December 2023, 1,503 patients were enrolled and randomly assigned to nicorandil (n = 748) or placebo (n = 755). The primary composite outcome occurred in 98 patients (13.1%) in the nicorandil group (113 events over 717.2 person-years) and 99 (13.1%) in the placebo group (136 events over 710.3 person-years), with no significant difference between groups (rate ratio: 0.869; 95% CI: 0.650-1.162; P = 0.3429). Among secondary outcomes, nominal reductions were observed in cardiovascular death (1.9% vs 3.6%; HR: 0.515; 95% CI: 0.269-0.983) and target-vessel revascularization (1.1% vs 3.0%; HR: 0.322; 95% CI: 0.143-0.727), whereas rates of nonfatal myocardial infarction and unplanned hospitalization for heart failure were similar between groups. Adverse events did not differ between groups. CONCLUSIONS: In patients with STEMI undergoing primary percutaneous coronary intervention, adjunctive intravenous nicorandil did not significantly reduce the 12-month primary composite outcome. These findings do not support routine use of intravenous nicorandil in unselected patients with STEMI. (Clinical Efficacy and sAfety of Intravenous Nicorandil; NCT04665648).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Huang, Wu, Lu, et al. Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI: The CLEAN Randomized Clinical Trial. J Am Coll Cardiol. 2026. PMID: 42584383. doi:10.1016/j.jacc.2026.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。